Caveat Emptor: Direct-to-Consumer Supply and Advertising of Genetic Testing

This article has 4 intents: 1. to highlight the major players and targeted consumers in the realm of private access to genetic testing and DTC advertising. 2. to canvass arguments for and against private access to commercially available genetic testing. 3. to analyze the recent DTC campaign by Myriad as an example of what may be on the horizon for Canada. 4. to question the adequacy of Canada's current regulatory system to deal with advertisements of this nature and, by examining the routes taken in other jurisdictions, to explore the potential for an improved regulatory framework specific to genetic testing services.

[1]  Patients' rights to laboratory data: trinucleotide repeat length in Huntington disease. , 1996, American journal of medical genetics.

[2]  Wylie Burke,et al.  The complexities of predictive genetic testing , 2001, BMJ : British Medical Journal.

[3]  Harbinger of Hope or Commodity Fetishism: “Re-cognizing” Dementia in an Age of Therapeutic Agents , 2001, International Psychogeriatrics.

[4]  Bryn Williams-Jones,et al.  Where There’s a Web, There’s a Way: Commercial Genetic Testing and the Internet , 2003, Public Health Genomics.

[5]  A. Codori.  Psychological opportunities and hazards in predictive genetic testing for cancer risk. , 1997, Gastroenterology clinics of North America.

[6]  T. Brennan,et al.  Direct-to-consumer marketing of high-technology screening tests. , 2002, The New England journal of medicine.

[7]  Mark D. Levin.  Direct-to-consumer advertising of genetic testing. , 2003, JAMA.

[8]  J K Worden,et al.  Psychosocial factors associated with the public's willingness to pay for genetic testing for cancer risk: a structural equations model. , 2001, Health education research.

[9]  Michael M. Burgess,et al.  Providing Genetic Testing Through the Private Sector: A View From Canada , 2001 .

[10]  N. Holtzman,et al.  Are Practicing and Future Physicians Prepared to Obtain Informed Consent? The Case of Genetic Testing forSusceptibility to Breast Cancer , 1999, Public Health Genomics.

[11]  S. Hull,et al.  Reading between the lines: Direct-to-consumer advertising of genetic testing in the USA , 2001, Reproductive health matters.

[12]  J Emery,et al.  The challenge of integrating genetic medicine into primary care , 2001, BMJ : British Medical Journal.

[13]  T. Caulfield,et al.  Gene testing in the biotech century: are physicians ready? , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  Sara Chandros Hull,et al.  Limitations of direct-to-consumer advertising for clinical genetic testing. , 2002, JAMA.

[15]  N. Holtzman,et al.  The new genetics: Genetic testing and public policy , 1998, BMJ.

[16]  T. Caulfield,et al.  Creating needs? A review of survey data and concerns relevant to the commercialization of genetic testing. , 2001, Community genetics.

[17]  P. Harper.  Direct marketing of cystic fibrosis carrier screening: commercial push or population need? , 1995, Journal of medical genetics.

[18]  Rnold,et al.  PROMOTION OF PRESCRIPTION DRUGS TO CONSUMERS , 2002 .

[19]  W. McKellin,et al.  ‘There’s this thing in our family’: predictive testing and the construction of risk for Huntington Disease , 1999 .

[20]  S. Wolfe.  Direct-to-consumer advertising--education or emotion promotion? , 2002, The New England journal of medicine.

[21]  D. Wertz.  Patients’ and Professionals’ Views on Autonomy, Disability, and “Discrimination” , 1999 .